| Literature DB >> 27517046 |
Rosa Rojo1, Juan Carlos Prados-Frutos1, Ángel Manchón1, Jesús Rodríguez-Molinero1, Gilberto Sammartino2, José Luis Calvo Guirado3, Rafael Gómez-de Diego1.
Abstract
The aim of this study was to evaluate the effectiveness of techniques for soft tissue augmentation in the placement of immediate implants with and without provisionalization and to assess the quality of the reports in the literature. Randomized clinical trials, prospective clinical trials, and case series were included in this review. Clinical questions were formulated and organised according to the PICOS strategy. An electronic search was performed in PubMed, Cochrane Central Register of Controlled Trials, Scopus, and ISI Web up until June 2016. Interexaminer agreement on eligibility (k = 0.842; p = 0.103) and quality (k = 0.933; p < 0.001) was high. Methodological approaches were assessed using criteria based on design related forms designed by the Dutch Cochrane Collaboration. Finally, 14 papers were identified. In two studies, the implant survival was 90%; for the rest of the studies it was 100%. All studies reported favourable aesthetic, biological, and radiographic outcomes. Surgical and biomechanical complications of this technique were not relevant. This technique effectively compensates for the expected loss of volume of the oral soft tissues and maintains high success rates with good aesthetic results over time.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27517046 PMCID: PMC4969511 DOI: 10.1155/2016/7374129
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Flow chart of the literature search.
Checklist for quality assessment. N/A: not applicable; ∗: items applicable to prospective controlled clinical trial.
| Quality assessment of randomized controlled trials ( | Quality assessment of case series |
|---|---|
|
| N/A |
| (1) Were adequate methods used for randomization? ( | |
|
| |
|
|
|
| (1) Were patient characteristics well described for both groups? | (1) Were patient characteristics well described? |
| (2) Were site characteristics well described for both groups? | (2) Were site characteristics well described? |
| (3) Were there no disparities in terms of patient or site characteristics between the groups? | |
|
| |
|
|
|
| (1) Were the inclusion and exclusion criteria well described and the same for both groups? | (1) Were the inclusion and exclusion criteria well described? |
| (2) Did the study report consecutively treated patients? | (2) Did the study report on consecutively treated patients? |
|
| |
|
|
|
| (1) Were interventions for both groups clearly described? | (1) Was the intervention clearly described? |
| (2) Were all patients of the same group treated according to the same intervention? | (2) Were all patients treated according to the same intervention? |
|
| |
|
|
|
| (1) Was blinding used to assess the outcome? | (1) Was the outcome assessed by an investigator who had not been involved in the treatment? |
| (2) Were adequate methods used to assess the outcome? | (2) Were adequate methods used to assess the outcome? |
| (3) Were reproducibility data reported on the outcome variable(s)? | (3) Were reproducibility data reported on the outcome variable(s)? |
|
| |
|
|
|
| (1) Was the outcome clearly described? | (1) Was the outcome clearly described? |
| (2) Was an intention-to-treat analysis performed and was there low risk for selective loss to follow-up? | (2) Was the response rate acceptable and was the number of patients lost to follow-up clearly described? |
Studies excluded after quality assessment and reasons for exclusion.
| Authors | Study design | Reasons for exclusion |
|---|---|---|
| Grunder et al. [ | Case series | The inclusion and exclusion criteria were not clearly described; it is unclear whether patients were consecutively treated; outcome was possibly assessed by an investigator involved in the treatment; methods used to assess the outcome were unclear; no actual data on the outcome were available. |
|
| ||
| Fagan et al. [ | Case series | Patients characteristics were incomplete (teeth not described); site characteristics were incomplete (age not described); patients were not treated according to same intervention (delayed or immediate implant placement); outcome was possibly assessed by an investigator involved in the treatment; methods used to assess the outcome were unclear; no reproducibility data were reported; no actual data on the outcome were available. |
|
| ||
| Reinhardt [ | Case series | Patients characteristics were incomplete (conditions around teeth not described); site characteristics were incomplete (age not described); it is unclear whether patients were consecutively treated; outcome was possibly assessed by an investigator involved in the treatment; no actual data on the outcome were available. |
Characteristics of included studies. RCT: randomized clinical trial; PCT: prospective clinical trial; CS: case series; f: female; m: male; mo: months.
| Authors, year | Study design | Follow-up (mo) | Country | Teeth | Sample | Mean age (range of years) | Number of implants evaluated |
|---|---|---|---|---|---|---|---|
| Migliorati et al., 2015 [ | RCT | 24 | Genova, Italy | 14 to 24 | 48 (25 f/23 m) | 47,5 (22 to 70) | 47 |
| Bianchi and Sanfilippo, 2004 [ | RCT | 72 to 216 | Milano, Italy | 17 to 27 and 37 to 47 | 116 (58 f/58 m) | 45,4 (19 to 73) | 116 |
| Yoshino et al., 2014 [ | RCT | 12 | Loma Linda, CA | 14 to 24 | 20 (13 f/7 m) | 52,6 (27 to 87) | 20 |
| Rungcharassaeng et al., 2012 [ | PCT | 17 | Loma Linda, CA | 13 to 23 | 24 (11 f/13 m) | 45,4 (23 to 87) | 23 |
| Cornelini et al., 2008 [ | PCT | 12 | Rimini, Italy | 15 to 25 and 35 to 45 | 34 (15 f/19 m) | 43 (21 to 62) | 34 |
| Lee et al., 2012 [ | CS | 24 | Seoul, Korea | 11 and 21 | 10 (8 f/2 m) | 46,4 (22 to 56) | 11 |
| Kan et al., 2009 [ | CS | 12 to 48 | Loma Linda, CA | 13 to 23 | 20 (14 f/6 m) | 52,3 (18 to 71) | 20 |
| Kan et al., 2007 [ | CS | 12 | Loma Linda, CA | 13 to 23 | 23 (undefined) | 39,5 (25 to 63) | 23 |
| Nemcovsky et al., 2000 [ | CS | 6 to 8 | Tel Aviv, Israel | 15 to 25 | 24 (undefined) | 45,5 (29 to 65) | 26 |
| Tsuda et al., 2011 [ | CS | 12 | Loma Linda, CA | 14 to 24 | 10 (6 f/4 m) | 48 (35 to 70) | 10 |
| Chung et al., 2011 [ | CS | 12 | Loma Linda, CA | 15 to 25 and 35 and 45 | 10 (4 f/6 m) | 52,1 (22,7 to 67,1) | 10 |
| Covani et al., 2007 [ | CS | 12 | Lucca, Italy | 15 to 25 and 35 to 45 | 10 (5 f/5 m) | (42 to 55) | 10 |
| Jyothi et al., 2013 [ | CS | 12 | Karnataka, India | 15 to 25 and 35 to 45 | 10 (5 f/5 m) | 25,3 | 10 |
| Nemcovsky et al., 1999 [ | CS | 6 to 9 | Tel Aviv, Israel | 15 to 25 | 29 (undefined) | 44,5 | 33 |
Characteristics of the clinical procedure of included studies. N: no; Y: yes; SCTG: subepithelial connective tissue graft; IIPP: immediate implant placement and provisionalization; IIP: immediate implant placement; RPF: rotated palatal flap; TG: test group; CG: control group.
| Authors, year | Buccal flap | Membrane | Xenograft | Allograft | Autogenous | Provisionalization on implant crown | Groups (sample) | Surgical technique soft tissue augmentation |
|---|---|---|---|---|---|---|---|---|
| Migliorati et al., 2015 [ | N | N | Y | N | N | Y | TG (24), CG (24) | IIPP with SCTG (TG) and IIPP without SCTG (CG) |
| Bianchi and Sanfilippo, 2004 [ | N | N | N | N | N | N | TG1 (32), TG2 (42),TG3 (22), and CG (22) | IIP with SCTG (3 TGs) and IIPP without SCTG (CG) |
| Yoshino et al., 2014 [ | N | N | Y | N | N | Y | TG (10), CG (10) | IIPP with SCTG (TG) and IIPP without SCTG (CG) |
| Rungcharassaeng et al., 2012 [ | N | N | Y | Y | N | N | TG (31), CG (24) | IPP with SCTG (TG) and without SCTG (CG) |
| Cornelini et al., 2008 [ | Y/N | Y/N | N | N | N | Y | TG (17), CG (17) | IIPP with SCTG (TG) and IIPP without SCTG (CG) |
| Lee et al., 2012 [ | Y | Y | Y | N | N | Y | TG (10) | IIPP with SCTG (TG) |
| Kan et al., 2009 [ | N | N | Y | N | N | Y | TG (20) | IIPP with SCTG (TG) |
| Kan et al., 2007 [ | Y/N | Y | Y | N | Y | Y | TG (11), CG (12) | IIPP with SCTG (TG) and IIPP without SCTG (CG) |
| Nemcovsky et al., 2000 [ | Y | N | Y | N | N | N | TG (24) | IIP with RPF (TG) |
| Tsuda et al., 2011 [ | N | Y | Y | N | N | Y | TG (10) | IIPP with SCTG (TG) |
| Chung et al., 2011 [ | N | N | Y | N | N | Y | TG (10) | IIPP with SCTG (TG) |
| Covani et al., 2007 [ | N | N | N | N | N | N | TG (10) | IIP with SCTG (TG) |
| Jyothi et al., 2013 [ | Y | N | N | N | N | N | TG (10) | IIP with SCTG (TG) |
| Nemcovsky et al., 1999 [ | Y | Y/N | Y | N | N | N | TG (14 in 15 sites), CG (15 in 18 sites) | IIP with RPF used membrane (TG) and IIP with RPF used no membrane (CG) |
Patient profile: inclusion and exclusion criteria.
| Inclusion criteria | Exclusion criteria |
|---|---|
| Age ≥ 18 years | Systematic diseases that could alter tissue integration of dental implants (severe systematic problems) |
| Good oral hygiene | Pregnancy |
| Adequate native bone to achieve implant primary stability with sufficient bone volume with minimum dimensions of 3.3 × 12,0 mm or 3,25 × 15,0 mm or 3,5 × 13,0 mm | Alcohol or drug dependency |
| Presence of adequate gingival architecture with the surrounding dentition | Head and neck radiation treatment |
| Appropriate gingiva-to-underlying bone dimension facially (≥2 mm) and interproximally (4 to 6 mm) | Bruxism and/or parafunction |
| Adjacent teeth or implants without need for prosthetic restorations | A lack of stable posterior occlusion |
| Stable occlusion | Perforation and/or loss of the labial bony plaque after tooth removal and/or implant osteotomy |
| Adequate vertical dimension of the existing metal-ceramic prosthetic restorations | |
| Indications for periodontal treatment before the implant surgery | |
| Absence of periodontal disease | |
| Being without active infection | |
| Tobacco abuse | |
| No smoking |
Figure 2Forest plot for survival rate of proportion of implants evaluated. Proportion ratio corresponds to the percentage of survival implants between the total number of implants evaluated.
Survival rate of implant and survival rate of suitable aesthetic results. Total exposure time corresponds to the sum of exposure time of implants that survived the follow-up time, exposure time to the failure of implants lost during the observation time, and exposure time up to the end of follow-up time for the implants that did not complete the observation period due to any reason.
| Study | Year | Total implants evaluated | Mean follow-up (years) | Number of failures of the implants | Total exposure time | Estimated survival rate of the implants (per 100 years) | Estimated rate of suitable aesthetic results (per 5 years) |
|---|---|---|---|---|---|---|---|
| Migliorati et al. [ | 2015 | 47 | 2 | 0 | 96 | 100% | 65% |
| Bianchi and Sanfilippo [ | 2004 | 116 | 12 | 0 | 1392 | 100% | N/A |
| Yoshino et al. [ | 2014 | 20 | 1 | 0 | 20 | 100% | 100% |
| Rungcharassaeng et al. [ | 2012 | 23 | 2,5 | 0 | 60 | 100% | N/A |
| Cornelini et al. [ | 2008 | 34 | 1 | 0 | 34 | 100% | 32% |
| Lee et al. [ | 2012 | 11 | 2 | 0 | 20 | 100% | 70% |
| Kan et al. [ | 2007 | 20 | 2,5 | 0 | 50 | 100% | 84% |
| Kan et al. [ | 2009 | 23 | 1 | 0 | 23 | 100% | 35% |
| Nemcovsky et al. [ | 2000 | 26 | 0,7 | 0 | 17 | 100% | N/A |
| Tsuda et al. [ | 2011 | 10 | 1 | 1 | 10 | 90% | 30% |
| Chung et al. [ | 2011 | 10 | 1 | 1 | 10 | 90% | 60% |
| Covani et al. [ | 2007 | 10 | 1 | 0 | 10 | 100% | N/A |
| Jyothi et al. [ | 2013 | 10 | 1 | 0 | 10 | 100% | N/A |
| Nemcovsky et al. [ | 1999 | 33 | 0,8 | 0 | 23 | 100% | N/A |
|
| |||||||
| Total | Fixed effects | 6,018 (5,919–6,117) | 1,261 (1,111–1,410) | ||||
| Random effects | 6,526 (6,125–6,927) | 1,292 (1,029–1,555) | |||||
| df | 13 | 7 | |||||
|
| 0,001 | 0,001 | |||||
|
| 93,21% | 64,32% | |||||
Figure 3Forest plot for proportion of suitable aesthetic results rate of implants evaluated. Proportion ratio corresponds to the percentage of suitable aesthetic results between the total number of implants evaluated.